(Alliance News) - Pharmaceutical company AstraZeneca PLC on Monday reported positive updates for its Tagrisso and Lynparza treatments.
For Tagrisso, results from a prespecified exploratory analysis of the Adaura phase three trial showed AstraZeneca's drug demonstrated a clinically meaningful improvement in central nervous system disease-free survival in treating lung cancer. Central nervous system recurrence, when cancer spreads to the brain, is a frequent complication of epidermal growth factor receptor-mutated non-small cell lung cancer.
Tagrisso reduced the risk of disease recurrence in the brain by 82%, AstraZeneca said.
Meanwhile, the company said Lynparza has been recommended for marketing authorisation in the EU for the 1st-line maintenance treatment with bevacizumab of patients with homologous recombination deficient-positive advanced ovarian cancer.
The same drug also has been recommended for EU authorisation for patients with metastatic castration-resistant prostate cancer.
The approval for Lynparza for treating ovarian cancer was based on analysis of the Paola 1 phase three trial. The trial showed that Lynparza in combination with bevacizumab maintenance treatment reduced the risk of disease progression or death by 67%.
Lynparza's approval for treating prostate cancer was based on a subgroup analysis of patients with BRCA1/2 mutations from the Profound phase three trial.
Shares in AstraZeneca were down 0.9% at 8,670.48 pence each in London on Monday morning.
By Tapan Panchal; tapanpanchal@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Astrazeneca (AZN)
